Pipeline Density Surveillance
Monitor 70+ active programs across mechanisms (GLP-1, dual/triple agonists, amylin analogs, oral formulations) with real-time detection of phase transitions, trial results, and regulatory filings.
💊Pharmaceutical Intelligence
Obesity & *GLP-1 Intelligence*
The GLP-1 landscape is evolving faster than any therapeutic category in pharma history. With 70+ pipeline programs, shifting payer coverage, and new indications emerging quarterly, commercial and development teams are making billion-dollar decisions with yesterday's intelligence.
Behavior Labs delivers lifecycle decision intelligence purpose-built for GLP-1 and obesity programs — connecting competitive pipeline surveillance, payer access modeling, indication expansion strategy, and real-world evidence synthesis into a compounding intelligence substrate that evolves as fast as the market.
70+Active GLP-1 pipeline programs across all phasesSource: ClinicalTrials.gov, 2025
Value Proposition
Compounding Intelligence for the Fastest-Moving Category in Pharma
Traditional competitive intelligence cycles deliver quarterly snapshots of a market that changes weekly. Behavior Labs operates continuously — detecting pipeline signals, tracking payer policy shifts, monitoring congress data drops, and connecting them to your specific lifecycle position.
Indication Expansion Intelligence
Track the cascade from T2D to obesity to NASH to cardiovascular risk reduction to CKD. Model which indication sequences optimize label breadth, pricing corridors, and formulary positioning for your specific program.
Payer Access Modeling
Simulate formulary committee decisions across commercial, Medicare Part D, and Medicaid channels. Model the impact of step therapy requirements, prior authorization criteria, and employer coverage trends on addressable patient populations.
Supply and Manufacturing Intelligence
Assess capacity constraints, device delivery platform strategies, and manufacturing scale-up timelines that determine which competitors can actually serve demand — not just win approval.
Market Intelligence
The GLP-1 Market at Scale
A category defined by unprecedented growth, fierce competition, and rapidly evolving payer dynamics.
Projected global GLP-1 market by 2030
Active pipeline programs in obesity/GLP-1
Projected US adults eligible for treatment
Major payer policy changes in 2024 alone
0Weeks to full competitive landscape analysis vs. 3-month consulting cycleBehavior Labs benchmark data
0%Reduction in time to detect competitive pipeline shiftsBehavior Labs benchmark data
0+Months of additional strategic lead time through continuous monitoringBehavior Labs benchmark data
Navigate the GLP-1 Competitive Landscape
See how Behavior Labs delivers compounding intelligence for the fastest-moving therapeutic category in pharma.